Prediction of compounds that are active against a desired biological target is a common 2 step in drug discovery efforts. Virtual screening methods seek some active-enriched 3 fraction of a library for experimental testing. Where data are too scarce to train 4 supervised learning models for compound prioritization, initial screening must provide 5 the necessary data. Commonly, such an initial library is selected on the basis of 6 chemical diversity by some pseudo-random process (for example, the first few plates of a 7 larger library) or by selecting an entire smaller library. These approaches may not 8 produce a sufficient number or diversity of actives. An alternative approach is to select 9 an informer set of screening compounds on the basis of chemogenomic information from 10 previous testing of compounds against a large number of targets. 11 We compare different ways of using chemogenomic data to choose a small informer 12 set of compounds based on previously measured bioactivity data. We develop this 13 Informer-Based-Ranking (IBR) approach using the Published Kinase Inhibitor Sets 14 (PKIS) as the chemogenomic data to select the informer sets. We test the informer 15 compounds on a target that is not part of the chemogenomic data, then predict the 16 activity of the remaining compounds based on the experimental informer data and the 17 chemogenomic data. Through new chemical screening experiments, we demonstrate the 18 utility of IBR strategies in a prospective test on two kinase targets not included in the 19 PKIS. Using limited training data in both retrospective and prospective tests, 20 bioactivity fingerprints based on chemogenomic data outperform chemical fingerprints 21 in predicting active compounds in both standard virtual screening metrics and accurate 22 identification of hits from novel chemical classes.
Introduction 41
Early-stage drug discovery involves a search for pharmacologically active compounds 42 (hits) that produce a desired response in an assay on a protein function or 43 disease-related phenotype. The active compounds serve as starting points for further 44 structural optimization, with the ultimate goal of developing therapeutic agents. 45 Virtual screening (VS) can be an effective strategy for prioritizing compounds that can 46 lower high-throughput screening costs by reducing the experimental search to smaller, Fig 1. IBR (Informer-Based Ranking) for compound prioritization on a novel target. From a complete bioactivity data matrix (blue grid), a subset of informer compounds (green stars) are identified from the broader set of compounds (stars) that have been tested against a large set of targets (pink circles). A previously uncharacterized target (red circle) is assayed with just the informer compounds, and the new bioactivity data are used to reveal the new target's relationship to other targets. The combined data enable activity predictions (purple) on the remaining, non-informer compounds.
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We propose three novel IBR strategies: Regression Selection (RS), Coding Selection 125 (CS), and Adaptive Selection (AS). Each strategy consists of (i) an informer set 126 selection method that chooses a small number of compounds to be tested, based on 127 characteristics of the bioactivity matrix, and (ii) a compound ranking method that 128 leverages returned informer data to predict which of the untested compounds is active 129 against a new target not represented in the currrent bioactivity matrix. Underlying all 130 three strategies is the premise that targets may be naturally organized according to
The performance of each new IBR strategy was assessed prospectively by inspection 144 of the successful activity predictions, and retrospectively using common VS metrics, 145 including: Area Under the Receiver-Operator Characteristic Curve (ROCAUC) and 146 enrichment factor (EF). We also assessed each strategy's ability to retrieve structural 147 diversity among active compounds by computing the fraction of active scaffolds 148 identified in the top of the ranking. Further, we compared the proposed IBR strategies 149 to several simpler IBR approaches, including ones that use compound structure 150 information and similarity-based expansion, and ones that use marginal features of the 151 bioactivity matrix. 152 
Results

153
IBR strategies apply in the low-data regime. 154 We describe IBR strategies that require experimental testing of some new target of 155 interest on a small fraction of the compound library -the informer subset -with a 156 view to effectively prioritizing the remaining compounds for subsequent testing for 157 activity with the target. The complete IBR strategy thus has two parts: a scheme to 158 identify the informer subset and a scheme to prioritize the remaining compounds after 159 assay data have been obtained for the informer compounds. Initially, we may have no 160 assay data on the new target, though we typically have some such chemogenomic data 161 on related targets that populate a related sector of chemical space, in some sense. 162 Ideally, a successful IBR strategy might be applied in target-agnostic drug development 163 settings (for example, phenotypic targets or incompletely featurized targets), so we 164 intentionally exclude from each IBR strategy target-specific features, such as protein 165 sequences or structural information. 166 We described three novel IBR strategies that utilize statistical patterns in the 167 bioactivity matrix that is available prior to informer-set assay testing. Regression 168 Selection (RS), Coding Selection (CS), and Adaptive Selection (AS) all treat the target 169 space as being partitioned into clusters of targets so that, within each cluster, there is 170 some relevant similarity of the bioactivity profiles of the targets across the space of 171 tested compounds. These three strategies also posit that a small number of compounds 172 (the informer subset) have bioactivity profiles that are predictive of the cluster label 173 appropriate to any target, including the novel target of interest. RS, CS, and AS differ 174 in how they evaluate clusterings and potential informer subsets. For example, RS and 175 AS involve kmeans clustering of targets followed by regularized multinomial regression 176 to learn the relationship between compounds and cluster labels, but they differ in how 177 the regression is regularized and how the informer compounds are identified. In 178 contrast, CS forms a single objective function that simultaneously scores clustering 179 strategies and potential informer compounds. 180 Computationally simpler baseline IBR strategies are useful to consider, as they may 181 approximate practical experimental design scenarios. Baseline Chemometric strategies 182 (BC s , BC l , and BC w ) use chemical features for both informer selection and 183 non-informer ranking. Three different chemometric ranking strategies are used for the 184 non-informer ranking, as denoted by subscripts s, l, and w (described in detail in the 185 Methods). Here, clustering is applied on the compound space using the known chemical 186 structure (fingerprints) of the compounds (not used in RS, CS, or AS) in order to 187 identify informer compounds. Then, prioritization of the non-informers makes use of 188 various ways of ranking the chemical distance between bioactive informers and 189 non-informers. Alternatively, a Baseline Frequent-hitters strategy simply takes as 190 informer compounds those that show the highest rate of activity within the initial target 191 set (BF s , BF l , BF w ). Prioritization of non-informers uses chemical distance, as in the 192 5/38 chemometric methods. To simplify, we only report baseline results for each of our top 193 chemometric and frequent-hitters baseline strategies (BC w and BF w ). Outcomes for the 194 full set of baselines are available in Supplemental Information.
195
Performance of the IBR strategies was evaluated using two virtual screening metrics 196 that reflect successful prioritization of active compounds ROCAUC and Normalized 197 Enrichment Factor in top 10% of ranking (NEF10)). An additional metric Fraction of 198 Active Scaffolds Retrieved (FASR10) assesses the diversity of the active chemical 199 structures that were prioritized in the top 10% of the ranking.
200
Prospective tests of IBR strategies on novel kinase targets. 201 We applied the IBR strategies on two novel kinase targets outside of the PKIS1 and 202 PKIS2 target sets. These targets are phylogenetically distant from most of the human 203 protein kinases in the PKIS data sets, with relatively low sequence identity to the 204 nearest neighbors in the PKIS1/2 sets in comparison to kinase domain sequences 205 (Supplementary Figure S1 ). For Mycobacterium tuberculosis kinase PknB (UniProt ID: 206 P9WI81), the nearest neighbors were the human serine/threonine kinases MARK2 with their associated experimental bioactivity measurements in Supplementary Table S1 . 217 The assay results for the informer compounds selected by each of the IBR strategies 218 were used to rank the remaining non-informers in PKIS1 or PKIS2. To evaluate the 219 performance of the different methods, all of the available PKIS1 and PKIS2 compounds 220 were assayed on PknB or BGLF4. Experimental active/inactive labels were assigned 221 using µ+2σ percent inhibition (activity) thresholds in PKIS1: PknB=13.4% and 222 BGLF4=20.2%, and PKIS2: PknB=8.7% and BGLF4=12.5%, based on screening 223 results from the PKIS compound sets.
224
The RS and CS approaches were the only methods that recovered multiple hits and 225 active scaffolds in their top 10% of ranked compounds for both kinase targets and both 226 datasets ( Table 1) . RS managed to recover actives for PknB even though it did not 227 include any active compounds in its PKIS1 or PKIS2 informer sets (Table S2 ). The RS 228 method was also the best overall for BGLF4 on PKIS2, and tied as the best method for 229 PknB on PKIS1. CS was the best approach for PknB on PKIS2.
230
AS and the three BF baseline methods (BF w shown in Table 1 ) struggled for both 231 targets with the PKIS2 compounds, each identifying only a single hit. However, AS was 232 the best approach for BGLF4 on PKIS1 compounds. Finally, the three purely 233 chemometric baseline approaches (BC) (BC w shown in Table 1 ) were the worst overall, 234 in many cases failing to recover any hits. The best methods were the same when Retrospective tests of IBR strategies by cross validation on 237 PKIS1 data matrix.
238
As a further assessment of IBR methods, we conducted retrospective 
242
Each time, the bioactivity profile of the left-out target was predicted in the sense that 243 compounds were prioritized for activity against this one left-out target.
244
Results from PKIS1 LOTO cross validation are summarized in statistically significant (all p-values < 1 × 10 −5 ). The CS method also had statistically 251 better ROCAUC performance than all baseline models except BF l (p = 0.053). A 252 complete set of p-values from a pairwise comparison of the IBRs is available in Table S5 . 253 The hybrid baseline approaches, which use compound bioactivity profiles to select the 254 most broadly active compounds as informers, performed much better than the 255 chemometric approaches that use chemical features for informer selection. 256 We also compared strategies using enrichment factor (EF) as an alternative VS 257 metric that, like ROCAUC, reflects retrieval of active compounds ( Figure 3 ). The 258 maximal EF value that could be achieved on a target, however, depends on the active 259 fraction in the set. To address the variation in the extent of the class imbalance across 260 kinase targets (active fractions ranging from 0.01-0.12 in PKIS1) ( Figure S2 ), we apply 261 the normalized EF metric NEF10. The EF cutoff was also extended from a typical 1% 262 . IBR methods were evaluated on 224 PKIS1 targets using standard VS metrics that reflect active retrieval: ROCAUC and NEF10. FASR10 was also evaluated to reflect the chemical diversity of the actives retrieved. All baseline outcomes are shown in Figure S4 along with p-values from pairwise comparisons in Table S5 . *The only non-baseline IBR that fails to demonstrate statistical improvement (p <0.05) over all baselines is CS when using the ROCAUC metric. AŠidák multiple comparison correction was applied using 6 baselines against each non-baseline IBR. threshold out to 10%, due to the small number of compounds considered (n = 366). To 263 simplify comparison with the ROCAUC metric, we scale NEF10 such that a value of 0.5 264 reflects a random classifier (equivalent to random ranking or no enrichment) and a value 265 of 1.0 represents a perfect classifier, in which the top 10% has been maximally enriched. 266 Over the 224 targets considered in PKIS1, our three bioactivity-based models (RS, CS, 267 and AS) are statistically superior to all of the baseline approaches (all p < 1 × 10 −13 ). 268 The AS method had the strongest enrichment for active compounds, with median 269 NEF10 of 0.85 ± 0.13. This was better than the top frequent hitters model, BF l , which 270 had a median NEF10 of 0.74 ± 0.13 (p < 1 × 10 −9 ). The enrichment is even better 271 compared to the chemometric models, the best of which is BC w , providing a median 272 NEF10 of 0.60 ± 0.13 (p < 1 × 10 −9 ).
273
Another key characteristic of robust virtual screening performance is the recognition 274 of diverse active compound structures, rather than retrieval of only a subset of the 275 active chemotypes. Because of the high rate of failure for hits in follow-up hit-to-lead or 276 optimization efforts, we value methods that can retrieve as many active scaffolds as (0.29 ± 0.21), (with p < 1 × 10 −9 and < 1 × 10 −9 , respectively).
285
Effect of Informer Set Size
286
All IBR strategies require choosing the number of elements n A to include in the 287 informer set. Larger n A allows more information to be gleaned from intermediate 288 screening data, and therefore improved prioritization of non-informer compounds.
289
Marginal improvements in performance as a function of n A are expected to diminish as 290 n A increases, because of redundancies in the information gleaned as more activity data 291 accrues. Larger n A also leads, of course, to higher assay costs. The experiments 292 reported above used n A = 16, amounting to about 4% of the compounds in the 293 chemogenomics matrix.
294
To examine the relationship of informer set size to prioritization performance, we 295 applied IBR strategies on a range of informer set sizes. First, we considered AS, our 296 best performing IBR strategy. Figure S4 shows ROCAUC and NEF10 metrics from the 297 LOTO retrospective analysis of PKIS1 for n A varying from 9 to 28. Performance did not 298 vary greatly over this range. We also tested a wider range of informer set sizes (n A = 1 299 9/38 A comparison of models with respect to compound ranking performance as assessed by active enrichment in the top 10% of ranked compounds. Each model was evaluated on 224 targets through PKIS1 leave-one-target-out validation. NEF10 represents the fold-enrichment of actives in top 10% above random that is normalized by dividing by the maximum theoretical fold-enrichment that could be achieved at the 10% threshold for the target of interest.
to 48 compounds) on PKIS1 target predictions using LOTO cross validation, and 300 examined ROCAUC and NEF10 using baseline IBR methods BC w ( Figure S5 ) and BF w 301 ( Figure S6 ). Over this range, we observe performance degradation with diminishing 302 informer set sizes. These experiments indicate that our preferred value n A = 16 strikes 303 a reasonable balance between size and performance for this particular data set.
304
Discussion
305
We set out to establish effective strategies to prioritize compounds for initial testing in 306 iterative high-throughput screens in a drug discovery setting. Our approach is related to 307 the cold-start problem in collaborative filtering (recommender systems) and involves 308 informer-based ranking (IBR) strategies that identify a small subset of highly 309 informative compounds to test in the initial screening round. Data obtained by testing 310 the informers can be used to prioritize compounds for subsequent screening. As a proof 311 of concept, we focused on kinases, so that we could test methods using public kinase 312 chemogenomic data matrices. Among the IBR strategies tested, we found that those 313 that leveraged bioactivity data from matrix targets (RS, CS, and AS) provided better 314 initial sampling than baseline strategies that applied chemometric similarity methods 315 (BC) or hybrid approaches (BF). (The hybrid approaches used a "frequent hitters" 316 heuristic for informer selection, based on matrix activities, and chemometric similarity 317 for ranking.) 318 We applied our chemogenomic IBR and baseline methods in prospective tests on two 319 microbial kinases: PknB and BGLF4. An initial batch of just 16 informer compounds 320 from each set (roughly 4% of the complete set of compounds) was selected for assays on 321 PknB and BGLF4. The methods were evaluated with regard to hit prioritization and 322 Fig 4. A comparison of models with respect to the structural diversity of the active compounds retrieved. Each model was assessed by FASR10 evaluations on 224 targets through PKIS1 leave-one-target-out validation. The FASR10 metric is the fraction of the total identified active molecule scaffolds, for the target of interest, that were identified in the top 10% of the ranked compounds on that target. Compounds are grouped by their generic (all-carbon skeletons) representations of Bemis-Murcko scaffolds. diversity of active scaffolds prioritized, compared to the results of assays of the PKIS1 323 and PKIS2 compounds. Results from these prospective tests indicated that IBRs using 324 bioactivity data and hybrid baseline IBRs outperformed baseline IBRs that use purely 325 chemometric data.
326
For a more complete assessment of the IBRs, we performed a retrospective 327 leave-one-target-out validation on the PKIS1 matrix (m = 224 targets by n = 366 328 compounds) using a batch selection of 16 informer compounds. We observed 329 statistically better hit prioritization and active scaffold retrieval for the purely 330 bioactivity-based IBRs (RS, CS, and AS) than for any of the baseline methods. [25] showed that simple kernel approaches using nearest proxy targets could be used 341 to rank compounds effectively for a query target (class 2), as long as it was possible to 342 identify proxy targets closely related to the query target. For kinase targets, Cichonska 343 et al.
[24] explored a wide range of ligand and target kernels to address class-1 and 344 11/38 class-3 problems. For focused target sets (kinases and GPCRs), Janssen et al. [26] 345 recently applied nearest-neighbor approaches to ligand and targets mapped on t-SNE 346 projections to address class-2 and class-3 problems.
347
The methods we report differ from prior chemogenomic methods for addressing the 348 class-2 problem by involving strategic but limited data acquisition on the query target. 349 Determination of the responses of targets to key informer compounds shifts a relatively 350 difficult class-2 problem into the more tractable class-1 problem of imputation. Unlike 351 chemogenomic kernel-based approaches [24, 25], we did not use target features, focusing 352 instead on target-agnostic strategies for compound ranking that could be used in the There are several potential uses for IBRs in drug discovery. This work demonstrates the 401 possibility of effective prediction of activities for new targets within the same target 402 class (kinases) from an extensive chemogenomics data matrix representing many targets 403 within that class. A future direction of research is to quantify the amount of 404 chemogenomic data needed to enable robust prediction within the same target class. It 405 appears that low-rank structure in the chemogenomic matrix used in the IBR methods 406 helps to enable reliable predictions of a target's compound preferences. Statistical 407 models that faithfully represent variation and dependence in bioactivity data also could 408 be leveraged to guide the development of alternative IBR strategies beyond RS, CS, and 409 AS.
410
Of greater interest is the development of a more general informer set from a broader 411 collection of chemogenomic data. To investigate the generalizability of the methods, we 412 plan to apply them to a wider range of novel targets (or held-out targets) using an 413 expanded chemogenomic data set with broader target and compound coverage. We do 414 not know how well IBRs will perform on new targets that are unrelated to those within 415 the matrix. We are encouraged by the prospective predictive performance on query 416 kinases (PknB and BGLF4) that are dissimilar from kinases in the chemogenomic data, 417 but note that these targets are still related functionally. More comprehensive data 418 matrices tend to be incomplete, with many missing data values, but they should be 419 useful in testing whether these methods are effective in extended pharmacological spaces. 420 The size of the informer set may well have a dramatic impact on overall performance.
421
It may be possible to use IBR methods for prioritizing non-matrix compounds on a 422 new target (a class-4 problem). Chemogenomic matrices enable pharmacological 423 mapping of a given new target (query) to matrix targets that exhibit similar bioactivity 424 profiles (proxy targets). Associations between query targets and proxy targets can be 425 made on the basis of full-compound bioactivity profile in the matrix, or potentially just 426 informer assay results. Given that certain proxy targets are likely to be more 427 extensively screened (tested with compounds outside the matrix set), it might be 428 possible to use non-matrix screening data on proxy targets to infer activities for 429 additional compounds and thus prioritize them for testing on some query target. We let X = {x i,j } m i=1 , n j=1 denote the bioactivity inhibition matrix that is available 459 initially, where m denotes the number of kinase targets and n denotes the number of 460 compounds. We use x i· for the vector of bioactivity results on target i, and x ·j for 461 column entries of this matrix (that is, bioactivity results for compound j). Let 462 I = {1, 2, · · · , m} denote the targets associated with rows of the data matrix X, and 463 J = {1, 2, · · · , n} denotes the set of available compounds.
464
For some methods, the kinase inhibition matrix X is reduced to a binary matrix
, which captures empirical assessments of whether target i is inhibited 466 (or not) by compound j. We use a target-wise threshold criterion (Eq. 1), based on the 467 sample mean and sample standard deviation of each row x i· , as follows:
Our ultimate task is prediction from X of binary activities: z i * ,j , on a new target i * ∈ I 469 for available compounds, j ∈ J. Our approach is first to identify from X a small 470 informer set of compounds, A ⊂ J, on which bioactivity data x i * ,j will be measured 471 against target i * . The data obtained from this experiment with the informer set, 472 denoted by x * = {x i * ,j , j ∈ A}, will be used to identify other compounds in the full 473 compound set J that inhibit new target i * , in the sense that z i * ,j = 1. Machine-learning 474 and statistical tools are used to design and study this approach, but except through 475 general parallels with adaptive experimental design, the selection of an informer set is 476 neither a supervised nor an unsupervised machine-learning task. We describe three 477 novel heuristic methods that have favorable empirical characteristics: regression 478 selection (RS), coding selection (CS), and adaptive selection (AS).
479
The informer-based ranking (IBR) methods that we propose entail partitions of the 480 target set I, also referred to as a set of clusters, sometimes denoted by clustering is used to partition the target space; then the informer set is chosen from 490 compounds that are predictive of cluster labels in a coupled, supervised analysis.
491
Informer set. The informer set is identified using clustering, regression, and feature 492 selection. First, we classify the target space -the row space x i· -into clusters such 493 that all targets within the same cluster exhibit a similar response to the compounds.
494
For this task we considered k-means, which tries to minimize the sum of the 495 within-cluster distances from each cluster centroid. Formally, given a parameter K as 496 the number of clusters, and m data vectors x i· , . . . , x m· , it aims to solve
where S = {S 1 , . . . , S K } forms a partition of I = {1, · · · , m}, and |V | denotes the 498 cardinality of the set V . For robustness, we scale each column of the bioactivity data X 499 linearly so that its entries lie in the range [0, 1] prior to clustering analysis.
500
There are two difficulties in using k -means. The first is that its iterative process 501 relies on random initialization, hence the results generally differ on each run. Secondly, 502 we do not know in advance how to specify the number clusters K. To deal with the first 503 problem, we use the kmeans++ initialization procedure [32] . kmeans++ guarantees that 504 the expected final objective value is no more than O(log K) times larger than the 505 optimal. To further improve robustness, we repeat the kmeans++ procedure 100 times 506 and choose the outcome that has the lowest objective value in Eq. 2. For the second 507 issue of selecting K, we find the value that achieves the best performance in a five-fold 508 cross-validation procedure.
509
Clusters serve to label the targets, as noted above. Namely, we set y i = k if i ∈ S k in 510 Eq. 2. Next, multinomial logistic regression with a penalty term is applied to train a 511 label classifier. In this approach, training data has the form {(x i· , y i )}, over an 512 appropriate set of targets i. The multi-class classifier is trained by fitting the 513 multinomial logistic model. That is, we seek a set of coefficients, 514 ω = {ω 10 , · · · , ω K0 , ω 1 , · · · , ω K }, by minimizing the objective function
where the first term is the (negative) log-likelihood from the multinomial logistic model, 516 λ ≥ 0 is a tuning parameter, and R(ω) is a penalty function. The coefficients ω k , one 517 for each cluster, are vectors whose length equals the number of compounds, each of 518 whose elements (ω k ) j represents the weight that is applied to the activity measurement 519 for compound j in predicting membership of cluster k. An appropriately chosen penalty 520 yields sparse solutions in which coefficients of compounds that are only weakly 521 predictive of the target cluster are set to zero. Since the whole coefficient vector 
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where u = u 2 = √ u T u denotes the L 2 -norm. 527 We combine this regularized model with the greedy heuristic proposed in [34] , which 528 was shown to outperform the model obtained by directly solving Eq. 3 by choosing 529 relevant features greedily, one at a time. This algorithm starts by setting A = ∅, then 530 solves Eq. 3, and then selects the feature vector ω ·j with the largest Euclidean norm, 531 from among those features still represented in the regularization term R. It adds j to 532 the informer set A, then re-solves Eq. 3 with all feature vectors ω ·j for j ∈ A excluded 533 from R. This process is repeated until either we have selected enough features (denoted 534 by n A ) or else the remaining ω ·j included in the norm calculation are all zero. After 535 selecting the features in this fashion, we retrain a model by solving Eq. 5 again using 536 only the selected features and omitting the regularization term R altogether, that is,
, such that ω ·j = 0 for j / ∈ A. (5)
Compound ranking. Given any new target and its bioactivity with compounds 538 from the informer set, we use the trained logistic regression model to predict the cluster 539 label. With y i * denoting the to-be-predicted cluster label of the new target i * and x * 540 the informer set compound activities for this target (i.e., the intermediate data), the 541 multi-class logistic model asserts:
Using this probability and the centroids, we predict the whole activity vector of the new 543 target with the vector of expected values:
for compound j.
545
Parameter estimation. Given the whole active prediction procedure, we are able to 546 conduct parameter selection using cross-validation. We conduct five-fold cross-validation 547 to pick the best value of K for each evaluation metric and then retrain on the whole 548 data matrix using the selected K to generate the final model for predicting the test 549 data. Pseudo-code for the entire regression selection process is provided in Algorithm 1 550 in the Supplementary Information. We fix λ = 10 −6 in Eq. 3 in our implementation.
551
Coding Selection (CS)
552
Coding selection works directly on the binary bioactivity data Z = {z i,j } i∈I,j∈J rather 553 than the quantitative inhibition measurements. The idea is to construct a single 554 objective function to score potential informer compounds for how well they predict 555 target activity the non-informer set. For a potential informer set A ⊂ J, CS considers 556 that distinct rows of the sub-matrix Z A = {z i,j } i∈I,j∈A constitute a kind of encoding of 557 the kinase target space. Specifically, row i of Z A , which corresponds to kinase target i, 558 is a length n A = 16 vector of zeros and ones. Among the 2 16 = 65536 possible such 559 vectors, only a relatively few distinct ones, numbering L A ≤ n, manifest themselves as 560 rows of the sub-matrix in a given example. We call these distinct vectors code words, 561 and denote them q 1 , q 2 , · · · , q L A . For some K ≤ L A , we introduce a partition π = {b k } 562 of these code words, where each block b k holds a set of code words, and where π has K 563 disjoint blocks. Together, the informer set A and the partition π induce a partition 564 16/38 S = {S 1 , S 2 , · · · , S K } of the targets I by the rule that i ∈ S k if (and only if) row i of 565 the sub-matrix equals some code word q l ∈ b k . We emphasize that given candidates A 566 and π, the target-space partition S is obtained using only information in the binary 567 data sub-matrix Z A .
568
To provide some intuition for the coding construction, let's look ahead to when 569 intermediate data x * are obtained in experiments with informer set compounds j ∈ A 570 on new target i * . These inhibition measurements may also be binarized to produce 571 bioactivity calls z * = {z i * ,j , j ∈ A}. If z * exactly matches one of the code words q l , 572 then any targets in I having this same code word are natural comparators for i * . Their 573 bioactivity profiles on the non-informer compounds may be the basis for a useful 574 secondary prediction. In fact we may not have an exact match of the new code word, 575 and there may be distinct code word profiles on the informer compounds that yield 576 similar non-informer profiles. Therefore, we propose the following objective function to 577 measure properties of the potential informer set A and the code-word partition π that 578 are conducive to high-accuracy prediction on non-informer compounds:
The inner summation in Eq. 8, which is over pairs of targets within cluster S k , essentially non-parametric, allowing potentially complex relationships to exist between 589 bioactivities of informer and non-informer compounds. This modeling flexibility comes 590 at a cost, however, in that it is a combinatorial optimization task to identify the best A 591 and π settings for any fixed K and λ.
592
Initially we sought to solve arg min f K,λ (A, π) approximately by Monte Carlo search. 593 Fixing parameters K and λ, we randomly sample (A 1 , π 1 ), (A 2 , π 2 ), · · · , (A B , π B ) for a 594 large number of trials B, such as 10 6 or 10 7 . Each A b is a random subset of size n A = 16 595 taken from the full set of n compounds; then π b is a random partition of the code words 596 from Z A b . In numerical experiments, we found that marginally stabilizing compound 597 scores is more effective than taking the informer setÂ to be the sampled set A b having 598 the lowest objective value (Eq 8). Specifically, we score every compound j ∈ J by
where K is a set of entertained cluster numbers. We used K = {2, 3, · · · , 40}, and fixed 600 λ = 5 based on preliminary experimentation. The computed informer setÂ contains the 601 n A best (lowest) scoring compounds by this score.
602
Compound ranking. To proceed with ranking compounds, we require a code word 603 z * derived from the intermediate data x * obtained on the new target i * . A threshold 604 level, such as used to binarize the original data (Eq. 1), may not be available. Instead 605 we revert to the inhibition data on the informer compounds, say XÂ (an m × n A 606 sub-matrix of X), and we keep track of all the rows of XÂ associated with each code 607 17/38 word in the computed informer set. We compute a centroid for code-word q l , say, c l , by 608 averaging the rows of XÂ associated with q l . Then, the code-word centroid that is 609 closest (in Euclidean distance) to the new data x * is the derived code word z * for target 610 i * .
611
Having our new target i * provide code word z * on the basis of intermediate data x * , 612 we next require a prediction of non-informer compounds that may also inhibit i * . We 613 score j ∈Â c by their activity rates among the n * targets with the same code word as i * : 614
(10) Our prediction of the active non-informer compounds is L = {j ∈Â c : a j ≥ κ} for some 615 threshold κ. We set κ with an appeal to false-discovery-rate (FDR) control, recognizing 616 that the Bernoulli trial z i * ,j may be regarded as having success probability estimated by 617 a j /n * . Then a crude estimate of FDR of L is
Similarly, we could estimate under the Bernoulli model the expected number of active 619 non-informer compounds, j∈A c (a j /n * ), which may guide our choice of κ.
620
Pseudo-code for the entire coding selection method is provided in Algorithm 2,
621
Supplementary Information.
622
Adaptive Selection (AS) 623 The AS approach first identifies a base informer set of size n 0 < n A compounds by a 624 minor variation of the regression selection (RS) approach. We use n 0 = 8 and n A = 16. 625 This step establishes both a clustering of the target space and the identity of n 0 626 compounds that are predictive of the cluster labels. Next, AS adaptively grows the 627 informer set, one compound at a time, so as to identify compounds that are predictive 628 of non-informer bioactivity.
629
To identify the base informer set A o , the target space I is clustered using k-means, 630 which aims to solve Eq. 2. With L K = min S K k=1
, the 631 number of clusters K is determined by
is a small value. In our calculations, = 0.02. Similar to RS, the clustered target 633 space {S k } then serves as the response variable in a penalized multinomial regression to 634 select the first n 0 compounds of the informer set. Our specific implementation uses 635 group LASSO as deployed in the glmnet R package for the multinomial response [35] . 636 The regularization penalty is chosen so that precisely n 0 compounds enter the predictive 637 model.
638
For the remaining n A − n 0 informer compounds, we augment the current set one 639 compound at a time. Letting A c denote the current set, the next added compound 
where x ·k is the column vector in the inhibition matrix {x i,j } i∈I,j∈J for compound k; 642 c n = 1 |Ac∪{j}| k∈Ac∪{j} x ·k denotes the centroid of the current informer set. Eq. 13 643 finds the compound that minimizes the distance between informers and non-informers; 644 18/38 the informer set is updated A c ←− A c ∪ {j * }. The final informer set is generated by 645 iterating this process until there are n A compounds in A c .
646
For compound ranking, AS uses the same approach as CS (Eq. 11 ) after the code 647 word z * is acquired on generated informer set. Pseudo-code for AS is provided in 648 Algorithm 3 of Supplementary Information. 649 Baseline Models (B) 650 As practical baseline approaches against which to compare our bioactivity-guided 651 experimental design strategies (RS, CS, and AS), we applied two different informer 652 selection methods: one based on compound structural diversity and the other leveraging 653 the most frequent hitter (nonselective) kinase inhibitors as observed from the compound 654 bioactivity matrix. Then, based on data returned from these informer selections, we 655 applied three different chemical feature-based compound ranking methods, yielding a 656 total of six strategies.
657
Baseline informer set selection. Baseline informer compounds were selected from each 658 data matrix by one of two different methods:
659
• Chemometric selection (BC) -Compounds are grouped by scikit-learn's 660 hierarchical agglomerative clustering procedure (n A = 16 clusters, average linkage) 661 using a Jaccard distance matrix computed from RDKit-derived Morgan chemical 662 fingerprints (radius=2, 1024-bits) as features [36] [37] [38] . The 16 cluster medoids are 663 taken as the informers.
664
• Frequent Hitters selection (BF ) -Matrix compounds j are ranked in descending 665 order by the number of targets on which each is labeled active, i.e., by 666 f j = i∈I z i,j , where z i,j indicates activity in the input bioactivity data (1) . In 667 other words, the informer set contains the 16 most broadly active compounds.
668
Note that in the cross validation study, the informer set needs to be recomputed 669 each time target is left out.
670
Baseline compound ranking. After data are returned on the informer set, the remaining 671 non-informer compounds were then ranked by three chemometric "hit expansion" 
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Each noninformer compound, j, has a similarity vector v representing the 688 compound's similarity to each of the informers tested on target i * :
The weighted expansion score, w, for compound j on target i * is then the 690 Euclidean Inner product:
In the simple and loop expansion ranking methods, a binary label is required to 692 designate "active" and "inactive" informers. This is problematic because this label 693 depends on a target's compound activity distribution (µ+2σ threshold), which is 694 unknown prior to experimental screening of the compound set. To address this issue, we 695 predict the activity threshold used for assigning a compound's binary activity label on a 696 given target using data returned on the 16 informer compounds. From these 16 informer 697 activities, a threshold is inferred threshold from the available compound activity 698 distributions on other targets in the matrix. This threshold for each target is the kappa 699 parameter described above in the Coding Selection method. 
where B is the set of compounds among the top 10% of those ranked by a method 742 applied to target i, and z i,j is as in (1) .
743
However, the number of active compounds for each left-out target i varies from 744 target to target ( Fig S1) . We apply a scaling scheme on EF at the top 10% (Eq 18), 745 which enables better comparisons across targets exhibiting significant differences in 746 active:inactive ratios.
where EFbase is 1, which corresponds to random guessing; EF10max i is the maximum 748 theoretical EF10 i , which means all actives are ranked at the top and depends on the 749 number of actives for each target. Our NEF metric returns a value between 0.5 and 1, 750 where a NEF10 i larger than 0.5 shows better ranking performance than random 751 guessing-similar to ROCAUC. We selected the 10% threshold with consideration of the 752 sizes of our informer (n A = 16) and full compound sets (n = 366 and n = 405). This 753 threshold includes the 16 informers and 21 noninformer compounds in our PKIS1 754 evaluation.
755
For the ROCAUC and NEF10 metrics, experimental percent inhibition (activity) 756 data were binarized using a target-specific µ+2σ threshold based on the activity 757 distribution of the PKIS1 compounds for the kinase target. Actives were defined as 758 compounds with greater than twice the standard deviations above the mean, as noted 759 in (1) . When applying the metrics, active informer compounds were counted as true 760 positives, whereas inactive informers did not count against the models as false positives. 761 It should be noted that the main purpose of the informer set is to facilitate accurate 762 activity ranking on the non-informers. However, since informer compounds represent 763 the highest priority compounds for testing, we reward models for retrieving active 764 informers but refrain from penalizing models for choosing inactive informers. Some If we then let z 10 i and O 10 J be the binary activity labels and scaffold IDs for the top 10% 780 ranked compounds, the subset of unique active scaffolds recognized just among the top 781 10% of compounds is:
The fraction of active scaffolds recognized in the top 10% is: Model evaluations. Performance of the models was evaluated in two stages. The first 792 stage follows a retrospective leave-one-target-out (LOTO) evaluation scheme. Each 793 kinase in the PKIS1 target set is removed and treated as a new target of interest. The 794 PKIS1 compound activities are hidden for this target. An informer set is selected for 795 this new target, the activities are revealed for the informers, and then the model rank 796 orders the remaining noninformers using the informer data. The 9 models were 797 evaluated in this stage using the 3 metrics described above. The second stage is a 798 prospective evaluation of the 9 models as applied on two novel, non-human, kinase 799 targets. In these evaluations, informer sets were generated twice for each model-once on 800 each of the training matrices, PKIS1 and PKIS2. The remaining compounds 801 (noninformers) from the corresponding matrix are then ranked on the two novel kinase 802 targets using data returned for the informer sets and data within the corresponding 803 PKIS1 or PKIS2 training matrix from which the informer set was selected. As in the 804 retrospective PKIS1 LOTO evaluation, each model was assessed using the 3 metrics rely on binary labels for informers (BC s , BC l , BF s , and BF l ), which are essentially hit 984 expansion strategies, exhibit a fairly significant failure rate in our PKIS LOTO 985 validation. These methods cannot proceed with non-informer ranking in cases where no 986 active informers are returned. For performance evaluations in the main text, we 987 considered these cases as methods' failures on a target and assigned the method-target 988 combination a performance metric reflecting a random ranking (e.g., ROC 0.5). Failure 989 rates were particularly high among those using chemometric informer selection methods 990 (BC s , BC l ), with no actives returned, and hence failure, on 68 of the 224 PKIS1 targets 991 (30.4%). As expected, our frequent hitters informer selection method (BF s , BF l ) has a 992 relatively lower failure rate with failure on 12 targets (5.4%). Given the high hit rates 993 for compounds within the PKIS1 matrix (5.6 +/-2.1% using target-specific µ+2σ 994 threshold), we anticipate that failure rates could be get much higher as we extend our 995 strategies to chemogenomic matrices with broader target sets, which are likely to be 996 26/38 more sparse. These issues are circumvented by ranking strategies that accommodate 997 continuous activity data and thus proceed with inferences based on weakly active 998 informers, rather than failing when no informers meet the active binary threshold. Thus, 999 the baseline w ranking strategies and all of the purely bioactivity based IBR strategies 1000 were not subject to this type of failure. 0.00 0.00 0.12 0.12 0.12 0.12 0.88 0.38 0.12 Table S4 . (a) ROCAUC, (b) NEF10, and (c) FASR10 in Leave-One-Target-Out Cross Validation on PKIS1. Nine IBR methods were evaluated on 224 PKIS1 targets using standard VS metrics that reflect active retrieval, ROCAUC and NEF10. FASR10 was also evaluated to reflect the chemical diversity of the actives retrieved. indicate p-values that fail to pass α = 0.05 threshold for significance between baseline methods. To collectively compare all 6 baseline IBRs against each non-baseline IBR, we imposed aSidák multiple comparison correction with 6 hypotheses. This increases the stringency of the statistical threshold applied on each of the 6 individual tests to α = 8.5E3. However, after applying this correction, non-baseline methods remained statistically superior to all baselines for all metrics except for CS when considering the ROCAUC metric. A sequence similarity matrix (% sequence identity of kinase domains) was determined for most members of the PKIS1 and PKIS2 kinase sets (mutants removed). The sequences of targets BGLF4 and PknB were also included. The histograms show the distribution of nearest-neighbor sequence identities among matrix kinases (PKIS1 or PKIS2). The blue (BGLF4) and red (PknB) diamonds indicate nearest neighbor sequence identities observed for these targets in the PKIS1 and PKIS2 kinase sets. BGLF4 and PknB do not have closely related neighbors in the sets. On these example kinase targets, separated regions of active chemical space can be observed.
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Fig S4. PKIS1 LOTO VS performance of AS method as function of informer set size. We examined the relationship between informer set size (n A =9 to 28) for IBR method AS and virtual screening performance in terms of ROCAUC and NEF10 metrics. 
